Literature DB >> 17707547

Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: a case report.

Etsu Tsuzuki Fuse1, Mitsuhiro Kamimura, Yuichiro Takeda, Makoto Kawaishi, Sosuke Kimura, Hitoshi Niino, Kiyoshi Saito, Nobuyuki Kobayashi, Koichiro Kudo.   

Abstract

A chemotherapeutic regimen for advanced thymic carcinoma has not yet been established. We describe a patient with advanced thymic mucoepidermoid carcinoma who achieved a complete response to combination chemotherapy with cisplatin (Randa) and irinotecan hydrochloride (Campto). A 74-year-old man was admitted to our hospital because of chest pain, general fatigue, appetite loss and weight loss. Chest computed tomography examinations revealed an anterior mediastinal tumour (5.5cmx3.5cmx9.5cm) that had invaded the subcutis through the sternum. The patient was treated with three courses of cisplatin and irinotecan hydrochloride followed by radiotherapy; he has since exhibited a complete response for 3 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707547     DOI: 10.1016/j.lungcan.2007.07.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  3 in total

Review 1.  Unusual combined thymic mucoepidermoid carcinoma and thymoma: a case report and review of literature.

Authors:  Shi-gang Wu; Yang Li; Bin Li; Xiao-ying Tian; Zhi Li
Journal:  Diagn Pathol       Date:  2014-01-20       Impact factor: 2.644

2.  Objective consensus from decision trees.

Authors:  Paul Martin Putora; Cedric M Panje; Alexandros Papachristofilou; Alan Dal Pra; Thomas Hundsberger; Ludwig Plasswilm
Journal:  Radiat Oncol       Date:  2014-12-05       Impact factor: 3.481

3.  Postoperative radiotherapy for thymus salivary gland carcinoma: A case report.

Authors:  Rui Deng; Nan-Jing Li; Liang-Liang Bai; Shi-Hong Nie; Xiao-Wen Sun; Yong-Sheng Wang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.